Tango Therapeutics, Inc. (NASDAQ:TNGX) Insider Mva Investors, Llc Sells 110,731 Shares of Stock

Tango Therapeutics, Inc. (NASDAQ:TNGX) insider Mva Investors, Llc sold 110,731 shares of the business’s stock in a transaction on Monday, July 1st. The stock was sold at an average price of $8.87, for a total transaction of $982,183.97. Following the completion of the sale, the insider now directly owns 203,793 shares in the company, valued at approximately $1,807,643.91. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Mva Investors, Llc also recently made the following trade(s):

• On Friday, June 28th, Mva Investors, Llc sold 29,000 shares of Tango Therapeutics stock. The stock was sold at an average price of $8.57, for a total transaction of $248,530.00.
• On Thursday, June 6th, Mva Investors, Llc sold 63,000 shares of Tango Therapeutics stock. The stock was sold at an average price of $7.24, for a total transaction of $456,120.00.
• On Friday, May 3rd, Mva Investors, Llc sold 60,000 shares of Tango Therapeutics stock. The stock was sold at an average price of $7.61, for a total transaction of $456,600.00.
• On Wednesday, May 1st, Mva Investors, Llc sold 75,000 shares of Tango Therapeutics stock. The stock was sold at an average price of $7.43, for a total transaction of $557,250.00.

Tango Therapeutics Price Performance

Shares of TNGX opened at $8.11 on Wednesday. The firm has a market capitalization of $866.02 million, a PE ratio of -7.17 and a beta of 0.83. The company’s 50-day moving average is $7.86 and its 200-day moving average is $9.27. Tango Therapeutics, Inc. has a fifty-two week low of $2.88 and a fifty-two week high of $13.03.

Tango Therapeutics (NASDAQ:TNGX) last released its quarterly earnings results on Wednesday, May 8th. The company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.31) by ($0.04). Tango Therapeutics had a negative net margin of 299.88% and a negative return on equity of 44.35%. The business had revenue of $6.47 million during the quarter, compared to analyst estimates of $7.13 million. Analysts predict that Tango Therapeutics, Inc. will post -1.31 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have issued reports on TNGX. Guggenheim raised shares of Tango Therapeutics to a “strong-buy” rating in a research report on Tuesday, May 28th. Wedbush dropped their price target on shares of Tango Therapeutics from $18.00 to $11.00 and set an “outperform” rating on the stock in a research report on Thursday, May 23rd. Barclays dropped their price target on shares of Tango Therapeutics from $18.00 to $13.00 and set an “overweight” rating on the stock in a research report on Friday, May 24th. Cantor Fitzgerald started coverage on shares of Tango Therapeutics in a research report on Thursday, April 4th. They issued an “overweight” rating on the stock. Finally, HC Wainwright dropped their price objective on shares of Tango Therapeutics from $16.00 to $13.00 and set a “buy” rating on the stock in a research report on Tuesday, May 28th. Six research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $14.17.

Hedge Funds Weigh In On Tango Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of TNGX. Charles Schwab Investment Management Inc. grew its stake in shares of Tango Therapeutics by 205.8% in the third quarter. Charles Schwab Investment Management Inc. now owns 367,357 shares of the company’s stock valued at $4,136,000 after acquiring an additional 247,234 shares in the last quarter. Invesco Ltd. grew its stake in shares of Tango Therapeutics by 3,247.3% in the third quarter. Invesco Ltd. now owns 774,738 shares of the company’s stock valued at $8,724,000 after acquiring an additional 751,593 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. grew its stake in Tango Therapeutics by 57.3% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 19,421 shares of the company’s stock worth $219,000 after buying an additional 7,077 shares in the last quarter. Adage Capital Partners GP L.L.C. grew its stake in Tango Therapeutics by 47.5% during the third quarter. Adage Capital Partners GP L.L.C. now owns 1,754,852 shares of the company’s stock worth $19,760,000 after buying an additional 564,971 shares in the last quarter. Finally, Vanguard Group Inc. grew its stake in Tango Therapeutics by 7.2% during the third quarter. Vanguard Group Inc. now owns 2,939,843 shares of the company’s stock worth $33,103,000 after buying an additional 197,624 shares in the last quarter. 78.99% of the stock is currently owned by institutional investors and hedge funds.

Tango Therapeutics Company Profile

Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.